BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 8, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 17, 2021
View Archived Issues
Positive interim data from phase I study of ALT-801 in overweight and obese volunteers
Read More
SpringWorks initiates phase I/II study of mirdametinib in children and young adults with LGG
Read More
Infex Therapeutics discloses new antibacterials
Read More
VenatoRx Pharmaceuticals synthesizes new carbapenem derivatives
Read More
Janssen Pharmaceutica presents new Mcl-1 inhibitors
Read More
Dunad Therapeutics and 2692372 Ontario, Inc. patent compounds for cancer
Read More
Japansese researchers describe new delta-opioid receptor agonists
Read More
Preclinical data for NVG-111: a ROR1xCD3 bispecific antibody
Read More
Second patient dosed in phase I/II MARVEL-1 study of FLT-190 in Fabry disease
Read More
Switching on prodrugs with radiotherapy shows promise
Read More
Paratek opens phase IIb study of Nuzyra in M. abscessus pulmonary disease
Read More
MacroGenics and Zai Lab collaborate on bispecific molecules in immuno-oncology
Read More
Safety data presented for BGB-11417 in R/R B-cell malignancies
Read More
Phase I/II trial of eprenetapopt in TP53-mutant AML meets primary efficacy endpoint
Read More
DSMB recommends phase I trial of rhenium nanoliposomes in GBM proceed to next cohort
Read More
Mydecine launches in silico drug discovery program with University of Alberta
Read More
Topline data from phase I study of NASH drug candidate ASC-42
Read More
Debiopharm and Ubix collaborate to develop antibody degraducer conjugates
Read More
CHN1 is a prognostic biomarker in DLBCL
Read More
Interim phase IIb/III data on CVnCoV show statistical success criteria not met
Read More
Apexigen and NSGO-CTU to collaborate on phase II study of sotigalimab for ovarian cancer
Read More
China's NMPA approves initiation of clinical trials of anti-Claudin 18.2 ADC SYSA-1801
Read More
Therapeutic Solutions reports preclinical data on low-dose naltrexone for schizophrenia
Read More
Early phase I data presented for LVGN-6051 as monotherapy and in combination with pembrolizumab
Read More
Loss of RKIP tied to aggressiveness in HNSCC
Read More
Biogen discontinues gosuranemab based on phase II data in Alzheimer's disease
Read More